Longevity & AgingSemaglutide's Expanding Reach: From Diabetes to Brain, Heart, and Liver
Semaglutide, a GLP-1 receptor agonist originally approved for type 2 diabetes, is proving effective across a remarkable range of conditions. This 2025 review synthesizes data from landmark trials including SUSTAIN, PIONEER, and STEP, showing reductions in HbA1c, up to 20% body weight loss, and fewer major cardiovascular events. Beyond metabolic effects, semaglutide demonstrates renoprotective, anti-inflammatory, and hepatoprotective properties. Emerging evidence supports its use in NAFLD, heart failure, polycystic ovary syndrome, obstructive sleep apnea, alcohol use disorder, and Alzheimer's disease. Both subcutaneous and oral formulations improve accessibility. Gastrointestinal side effects remain the primary concern, but long-term data affirm overall safety.
